Dr. Michael Marwan Haddadin, MD

Dr. Haddadin practices at Nebraska Medical Center in Omaha, Nebraska, part of University of Nebraska System.

Dr. Haddadin's NPI, 1780105064, was assigned on June 27, 2017. Dr. Haddadin holds Nebraska license 35770.

Dr. Haddadin's primary practice is Nebraska Medical Center, at 988102 Nebrasks Medical Center, Omaha, NE 68198 in Douglas County. The practice phone is (402) 559-4000. Dr. Haddadin also practices at Nebraska Medical Center, 987400 Nebraska Medical Ctr, Omaha, NE 68198.

Dr. Haddadin's primary practice is Nebraska Medical Center in Omaha, Nebraska, part of University of Nebraska System. Dr. Haddadin is also affiliated with Bryan Medical Center. The medical group on file is UNMC Physicians. Dmand AI also links Dr. Haddadin to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Haddadin practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Haddadin's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Haddadin is licensed in Nebraska.

CMS data shows 804 Medicare services from Dr. Haddadin across 6 procedure codes in 2024, for 121 Medicare patients. Medicare paid $61,890 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 121 Medicare patients who saw Dr. Haddadin in 2024. The largest group is 65 to 74, with 74 patients. 74% of them have high blood pressure, and 62% have high cholesterol. Their average risk score is 2.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Haddadin's median patient age at 71, with 45% women.

In 2024, Dr. Haddadin wrote 570 Medicare Part D claims for 45 patients. 78% of them were for generic drugs. CMS names the drug for 333 of them, across 15 drugs with 11 or more claims each, at $550,031 in total drug cost. In 2023, CMS named 84 claims across 6 drugs.

Dr. Haddadin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Haddadin as offering telehealth.

Dmand AI links 2 papers to Dr. Haddadin, published from 2024 to 2025. Dr. Haddadin's most frequent co-authors are Vijaya Raj Bhatt, MD, Krishna Gundabolu, MD and James O. Armitage, MD.

CMS Open Payments shows 29 general payments to Dr. Haddadin from 11 drug and device companies from 2023 to 2025. Consulting fees make up the largest share, 41% of the total. Syndax Pharmaceuticals, Inc. paid the most, $3,046.